AstraZeneca (AZN), and AbbVie (ABBV) are among the winners of positive drug recommendations in the EU this week. Read more ...

A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor ...

Merck (MRK.N), opens new tab said on Monday its experimental endometrial cancer drug met the main goals of a late-stage trial ...

The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...

Merck & Co. Inc. (NYSE:MRK) is one of the best low risk stocks to buy in 2026. On May 18, Merck announced that its pivotal ...

Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment combined with partner Merck's Keytruda ...

Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in ...

Biotech’s antibody-drug conjugate significantly improved progression-free and overall survival in a pivotal endometrial ...

Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.

New guidelines from two leading medical associations suggest that efforts to reduce bad cholesterol should focus on ...

Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...